



September 9, 2019

Migration of testing: infectious disease serology

At Dynacare, our vision is to be Canada’s health and wellness solutions leader. As part of our continuous efforts to enhance our testing platforms and support patient care, on September 9, 2019, Dynacare is implementing in Ontario a new state-of-the-art immunoassay platform for infectious disease serology. With the change in platform, Dynacare has reviewed the reporting parameters and will be making the following changes:

Effective September 9, 2019, the following changes will be made for infectious disease serology:

Test name on reports		Reporting verbiage		Reporting limits (if quantitative value is provided)	
Current	New	Current	New (if revised)	Current	New
ANTIBODY (IgG) TO HEPATITIS A ANTIGEN (HAVAb)	HAV TOTAL ANTIBODY	Negative/positive		\	
ANTIBODY (IgM) TO HEPATITIS A ANTIGEN (HAVAb-IgM)	HAV IgM ANTIBODY	Negative/borderline/reactive	Negative/positive	\	
ANTIBODY TO HEPATITIS B CORE ANTIGEN (HBcAb)	HBc TOTAL ANTIBODY	Negative/positive		\	
ANTIBODY TO HEPATITIS B e ANTIGEN (HBcAb)	HBe ANTIBODY	Negative/positive		\	
HEPATITIS B e ANTIGEN (HBcAg)	HBe ANTIGEN	Negative/positive		\	
ANTIBODY TO HEPATITIS B SURFACE ANTIGEN (HBsAb)	HBs ANTIBODY	Negative/positive		10-100 IU/L	2-1000 IU/L
HEPATITIS B SURFACE ANTIGEN (HBsAg)	HBs ANTIGEN SCREEN	Negative/positive	Negative/borderline/reactive	\	
HEPATITIS C VIRUS ANTIBODY (ANTI-HCV)	HCV ANTIBODY	Negative/positive		\	

Note: Anti-HBc-IgM and HBsAg confirmatory testing will not be migrating and will remain on the existing platform. No reporting changes will be made to Anti-HBc-IgM and HBsAg.

Note that anti-HBc-IgM and HBsAg confirmation testing will not be migrating and will remain on the existing platform. To improve reporting transparency, when HBsAg is reactive by the screening method, the HBsAg screen and confirmatory tests will be reported as separate results.

Dynacare is committed to providing the highest quality and value to our clients and to the healthcare system. For further information regarding these changes, please contact Customer Care at 800.565.5721 x 5752.

We appreciate your support and look forward to working with you as we strive to improve the quality of our services.

Peter Catomeris, PhD, FCACB
Scientific Director of Chemistry and Immunoassay